Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Key Laboratory for Endocrinology and Metabolism of Chinese Health Ministry, Rui-jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, China.
Endocrine. 2012 Apr;41(2):281-8. doi: 10.1007/s12020-011-9550-6. Epub 2011 Oct 28.
Chemerin is a newly discovered adipokine which has been found closely associated with obesity, metabolic syndrome (MetS), and inflammatory status. This study will investigate whether serum chemerin levels are associated with coronary artery disease (CAD) independently of other cardiovascular risk factors. This study included a total of 430 subjects (239 with CAD and 191 with non-CAD) who underwent coronary angiography. Anthropometric measurements were performed and chemerin, glucose, lipid profiles, and other biochemical characteristics were measured. The severity of coronary atherosclerosis was estimated by the total number of diseased vessels and Gensini score. Serum chemerin levels were significantly higher in the CAD group than in the non-CAD group (P = 0.011). The odds ratios (95% CI) of CAD across increasing quartiles of serum chemerin were 1.04 (0.61-1.78), 1.08 (0.63-1.83), and 1.87 (1.07-3.24), (P = 0.386, 0.508, and 0.012, respectively). Adjusting for age, sex, and other conventional risk factors for CAD did not appreciably alter the results. Serum chemerin levels were significantly increased with an increasing of number of diseased vessels (P = 0.024). In conditional linear regression models, chemerin levels were positively related to Gensini score even after established cardiovascular risk factors (β = 0.13, P = 0.019). Correlation analysis showed serum chemerin levels were significantly associated with TG levels, TC levels, fasting serum insulin, HOMA-IR and MetS (all P < 0.05). Higher serum chemerin levels were associated with increased risk of CAD and metabolic parameters in Chinese adults. Chemerin may represent a novel link between metabolic signals and atherosclerosis.
趋化素是一种新发现的脂肪因子,与肥胖、代谢综合征(MetS)和炎症状态密切相关。本研究旨在探讨血清趋化素水平是否与其他心血管危险因素独立相关。本研究共纳入 430 例患者(CAD 组 239 例,非 CAD 组 191 例),均行冠状动脉造影。进行人体测量学测量,检测趋化素、血糖、血脂谱和其他生化特征。通过病变血管总数和 Gensini 评分评估冠状动脉粥样硬化严重程度。CAD 组血清趋化素水平明显高于非 CAD 组(P = 0.011)。随着血清趋化素四分位数的升高,CAD 的比值比(95%可信区间)分别为 1.04(0.61-1.78)、1.08(0.63-1.83)和 1.87(1.07-3.24)(P = 0.386、0.508 和 0.012)。校正年龄、性别和其他 CAD 常规危险因素后,结果无明显变化。随着病变血管数的增加,血清趋化素水平显著升高(P = 0.024)。在条件线性回归模型中,即使在建立了心血管危险因素后,趋化素水平与 Gensini 评分呈正相关(β = 0.13,P = 0.019)。相关分析显示,血清趋化素水平与 TG 水平、TC 水平、空腹血清胰岛素、HOMA-IR 和代谢综合征显著相关(均 P < 0.05)。较高的血清趋化素水平与 CAD 风险增加和中国成年人的代谢参数相关。趋化素可能代表代谢信号和动脉粥样硬化之间的新联系。